C4X Discovery is a drug discovery and development company that aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high-value therapeutic areas. The company has various proprietary and synergistic software platforms, including Taxonomy3, Conformetrix, and 4Sight, which enable rational, accelerated 4D structural drug design using experimental data rather than theoretical data. C4X Discovery focuses on high-value disease areas such as inflammation, neurodegeneration, and cancer, and recently signed a licensing agreement with Indivior for a pre-clinical addiction program worth up to $294m.